Who is sponsoring NCT01084408?

NCT01084408 is sponsored by University Hospital, Saarland.

What drugs are being tested in NCT01084408?

Interventions in NCT01084408: SeQuent®Please (Paclitaxel coated balloon), Taxus™Liberté™ (Paclitaxel eluting stent).

What condition does NCT01084408 study?

NCT01084408 studies Coronary De-novo Stenoses.

Is NCT01084408 still recruiting?

NCT01084408 is currently terminated. Last updated 25 March 2021.

Last reviewed 2021-03-25 · How we verify

NCT01084408: PEPCAD-DEBonly

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of the SeQuent®Please in the Treatment of De-novo Stenoses Versus Taxus™Liberté™

Terminated Phase 3 Last updated 25 March 2021

What this trial tests

Phase 3 trial testing SeQuent®Please (Paclitaxel coated balloon) in Coronary De-novo Stenoses in 90 participants. Terminated before completion.

Timeline

1 March 2010

Primary endpoint
1 March 2012

1 March 2013

Quick facts

Lead sponsor	University Hospital, Saarland
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 March 2010
Primary completion	1 March 2012
Estimated completion	1 March 2013
Sites	2 locations across Germany

Drugs / interventions tested

SeQuent®Please (Paclitaxel coated balloon)
Taxus™Liberté™ (Paclitaxel eluting stent)

Conditions studied

Coronary De-novo Stenoses — all drugs for Coronary De-novo Stenoses →

Sponsor

University Hospital, Saarland

Who can join

19 and older, any sex, with Coronary De-novo Stenoses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the trial is to assess the efficacy of the Paclitaxel-coated SeQuent®Please angioplasty balloon in the treatment of stenoses in native coronary arteries compared to a drug eluting stent.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Saarland trials

Trials by the same sponsor.

NCT06150053 — Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL · completed
NCT04128384 — Infranodal Conduction Time During TAVR as Predictor of HAVB · NA · unknown
NCT03467087 — Safety and Feasibility of Electrical Muscle Stimulation During Stem Cell Transplantation or Intensive Chemotherapy · NA · completed
NCT03431532 — Monocyte Subsets Altered by Anesthesia · completed
NCT02226770 — Heart-focused Anxiety in Patients With Heart Failure and ICD · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01084408 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Saarland
Last refreshed: 25 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01084408.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing